Previously, Dr. Alexander held executive positions at big-name companies including Takeda Pharmaceuticals, Pfizer, AstraZeneca and Merck.
He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology.
“Robert’s extensive experience as a biotech industry veteran will be crucial as we continue to progress RE104 through the clinic and approach our phase 2 study launch in postpartum depression,” Greg Mayes, Reunion’s president and CEO, said in a Jan. 18 press release. “Following Reunion’s successful interim data analysis for its Phase 1 trial with lead asset RE104, Robert will further guide us in advancing RE104 to the next stage of development for the millions of patients in need.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.